Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Comparative efficacy and safety of infliximab and vedolizumab therapy in patients with inflammatory bowel disease: a systematic review and meta-analysis
Authors
Keywords
-
Journal
BMC GASTROENTEROLOGY
Volume 22, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-06-08
DOI
10.1186/s12876-022-02347-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Randomized Controlled Trial: Subcutaneous versus Intravenous Infliximab CT-P13 Maintenance in Inflammatory Bowel Disease
- (2021) Stefan Schreiber et al. GASTROENTEROLOGY
- Comparative Efficacy and Rapidity of Action for Infliximab vs Ustekinumab in Biologic Naïve Crohn’s Disease
- (2021) Neeraj Narula et al. Clinical Gastroenterology and Hepatology
- First- and Second-line Pharmacotherapies for Patients with Moderate to Severely Active Ulcerative Colitis: An Updated Network Meta-Analysis
- (2020) Siddharth Singh et al. Clinical Gastroenterology and Hepatology
- Comparative of the Effectiveness and Safety of Biological Agents, Tofacitinib, and Fecal Microbiota Transplantation in Ulcerative Colitis: Systematic Review and Network Meta-Analysis
- (2020) Hao-Yue Zhou et al. IMMUNOLOGICAL INVESTIGATIONS
- Efficacy and Safety of CT-P13 in Inflammatory Bowel Disease after Switching from Originator Infliximab: Exploratory Analyses from the NOR-SWITCH Main and Extension Trials
- (2020) Kristin K. Jørgensen et al. BIODRUGS
- Vedolizumab in Combination With Corticosteroids for Induction Therapy in Crohn’s Disease: A Post Hoc Analysis of GEMINI 2 and 3
- (2019) Bruce E Sands et al. INFLAMMATORY BOWEL DISEASES
- Efficacy and safety of biosimilar CT-P13 compared with originator infliximab in patients with active Crohn's disease: an international, randomised, double-blind, phase 3 non-inferiority study
- (2019) Byong Duk Ye et al. LANCET
- ACG Clinical Guideline
- (2019) David T. Rubin et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy and Safety of Vedolizumab Subcutaneous Formulation in a Randomized Trial of Patients With Ulcerative Colitis
- (2019) William J. Sandborn et al. GASTROENTEROLOGY
- British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults
- (2019) Christopher Andrew Lamb et al. GUT
- Vedolizumab versus Adalimumab for Moderate-to-Severe Ulcerative Colitis
- (2019) Bruce E. Sands et al. NEW ENGLAND JOURNAL OF MEDICINE
- ECCO Guidelines on Therapeutics in Crohn's Disease: Medical Treatment
- (2019) Joana Torres et al. Journal of Crohns & Colitis
- Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease
- (2018) S. Singh et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- ACG Clinical Guideline: Management of Crohn’s Disease in Adults
- (2018) Gary R Lichtenstein et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Real-world Evidence versus Randomized Controlled Trial: Clinical Research Based on Electronic Medical Records
- (2018) Hun-Sung Kim et al. JOURNAL OF KOREAN MEDICAL SCIENCE
- OUP accepted manuscript
- (2018) Journal of Crohns & Colitis
- Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis
- (2018) Brian G Feagan et al. INFLAMMATORY BOWEL DISEASES
- Vedolizumab as Induction and Maintenance Therapy for Crohnʼs Disease in Patients Naïve to or Who Have Failed Tumor Necrosis Factor Antagonist Therapy
- (2017) Bruce E. Sands et al. INFLAMMATORY BOWEL DISEASES
- Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial
- (2017) Kristin K Jørgensen et al. LANCET
- Ulcerative colitis
- (2017) Ryan Ungaro et al. LANCET
- Randomised clinical trial: deep remission in biologic and immunomodulator naïve patients with Crohn's disease - a SONICpost hocanalysis
- (2015) J.-F. Colombel et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Effects of Vedolizumab Induction Therapy for Patients With Crohn’s Disease in Whom Tumor Necrosis Factor Antagonist Treatment Failed
- (2014) Bruce E. Sands et al. GASTROENTEROLOGY
- Association Between Serum Concentration of Infliximab and Efficacy in Adult Patients With Ulcerative Colitis
- (2014) Omoniyi J. Adedokun et al. GASTROENTEROLOGY
- Validation of Endoscopic Activity Scores in Patients With Crohn's Disease Based on a Post Hoc Analysis of Data From SONIC
- (2013) Marc Ferrante et al. GASTROENTEROLOGY
- Clinical disease activity, C-reactive protein normalisation and mucosal healing in Crohn's disease in the SONIC trial
- (2013) Laurent Peyrin-Biroulet et al. GUT
- Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
- (2013) Brian G. Feagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
- (2013) William J. Sandborn et al. NEW ENGLAND JOURNAL OF MEDICINE
- Crohn's disease
- (2012) Daniel C Baumgart et al. LANCET
- Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
- (2011) William J. Sandborn et al. GASTROENTEROLOGY
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement
- (2009) David Moher et al. PLOS MEDICINE
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started